Adknoma Health Research
Adknoma Health Research is recorded as a service provider in 16 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 16 of 16 trials · Latest update first
An Open-Label Phase 2a Study to Evaluate the Safety, Tolerability, and Efficacy of Vafidemstat in Adults with Phelan-McDermid Syndrome (PMS) (HOPE-2).
Sponsor Oryzon Genomics S.A.
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of a post-coital intravaginal gel of PKB171 in couples with mild male factor infertility.
Sponsor Prokrea Bcn S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A Phase II, Multicenter, Open-Label, Single-Arm Study to Evaluate the Efficacy and Safety of Enfortumab Vedotin (EV) as a Single-Agent in Patients with G3 Neuroendocrine Tumours (NETs) or Advanced Neuroendocrine Carcinomas (NECs), Refractory to or Ineligible for Platinum-Based Chemotherapy.
Sponsor Grupo Espanol De Tumores Neuroendocrinos
- Start (EU)
- Latest update
- Estimated end
- Not reported
A double blind, randomized, placebo-controlled, adaptive 24-week Phase II trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia (EVOLUTION Study)
Sponsor Oryzon Genomics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Randomised, double-blind, placebo-controlled, active-treatment clinical trial to assess the analgesic efficacy and safety of an oral combination of ibuprofen (arginine)-tramadol hydrochloride administered to patients with moderate to severe pain after dental surgery.
Sponsor Farmalider S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Operational learnings available4 trial-level findings · Read insights
- The protocol planned to include 346 patients with moderate-to-severe post-dental-extraction pain; 556 subjects were recruited and 356 were randomized.
- Recruitment was suspended by the sponsor on 16 June 2022 because of low recruitment and restarted on 21 April 2023.
- The trial was conducted at nine maxillofacial-surgery clinics in Spain.
- A substantial amendment added one site in January 2022, and a further amendment added three sites in January 2024.
These findings describe the trial, not the service provider’s performance or responsibility.
RANDOMISED, MULTICENTRE, DOUBLE-BLIND CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF MONTELUKAST VS. PLACEBO IN PATIENTS WITH EROSIVE/INFLAMMATORY OSTEOARTHRITIS OF THE HANDS. MOTHER Study.
Sponsor Farmalider S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
MULTICENTER, RANDOMIZED, BLIND AND CONTROLLED CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF XXXXXX IN THE CORRECTION OF 25(OH)D DEFICIT IN SUBJECTS WITH SEVERE VITAMIN D DEFICIENCY, COMPARED TO XXXXXX. DTREAT STUDY.
Sponsor Itf Research Pharma S.L.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase III, double-blind, randomised, placebo- and active treatment-controlled clinical trial to evaluate the analgesic efficacy and safety of a combination of ibuprofen (arginate)-tramadol hydrochloride 400-37.5 mg, administered intravenously to patients with acute severe postoperative pain.
Sponsor Farmalider S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
GEM21menos65. A Phase III trial for NDMM patients who are candidates for ASCT comparing Extended VRD plus Early Rescue Intervention vs Isatuximab-VRD vs Isatuximab-V-Iberdomide-D.
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
Phase 2 study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea
Sponsor Oryzon Genomics S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
Prospective evaluation of the efficacy and safety of topical hydrocortisone treatment on clinical signs and symptoms of dry eye disease associated with moderate meibomian gland dysfunction
Sponsor Laboratorios Thea S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
A phase I-II, multicentre, open label clinical trial to assess the safety and tolerability of the combination of low-dose cytarabine or azacitidine, plus Venetoclax and Quizartinib in newly diagnosed acute myeloid leukemia patients aged equal or more than 60 years old ineligible for standard induction chemotherapy
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
Towards a treatment for accelerated maturation in girls testing spiomet in a randomised placebo controlled, multicentre study.
Sponsor Hospital Universitari De Girona Doctor Josep Trueta
- Start (EU)
- Latest update
- Estimated end
- Not reported
Pilot study to explore the diagnostic value of gadopiclenol in pathological and radiological insights with multiparametric MRI enhancement in breast cancer.
Sponsor Fundacion Ribera Salud
- Start (EU)
- Latest update
- Estimated end
- Not reported
A randomized, multi-centre, double-blind, phase II clinical trial of dose finding of Montelukast in patients with erosive osteoarthritis of the hands. HOME study.
Sponsor Farmalider S.A.
- Start (EU)
- Latest update
- Estimated end
- Not reported
An open label, multicenter, phase I/II study of belantamab mafodotin in combination with Kd for the treatment of relapsed myeloma patients, refractory to lenalidomide.
Sponsor Fundacion PETHEMA
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Adknoma Health Research?
The 2026-10-09 snapshot links Adknoma Health Research to 16 distinct CTIS trials. Recorded services include Clinical monitoring, Regulatory services, Project management, Data management, among 13 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Adknoma Health Research?
The most frequently recorded therapeutic areas are Genetic and Congenital Disorders, Gynecology, Neurology, Oral Health and Dentistry. Recorded phases include Phase 2, Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Adknoma Health Research conducted?
The linked trials record locations in 7 countries, including Spain, Bulgaria, Italy, Poland, Portugal. These are trial locations, not confirmed office locations or countries where Adknoma Health Research delivered services.
What can this page tell me about Adknoma Health Research's trial experience?
Browse 16 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. 1 trials have operational findings that can inform further due diligence. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Adknoma Health Research. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Adknoma Health Research S.L.